December 2025

Whole food diet induces remission in children and young adults with mild to moderate Crohn's disease and is more tolerable than exclusive enteral nutrition: A randomized controlled trial

Gastroenterology 2025;169:1462–74 Doi: 10.1053/j.gastro.2025.06.011

Aharoni-Frutkoff et al. demonstrated that tasty & healthy (T&H) ‘diet’ showed better tolerability than exclusive enteral nutrition (EEN) for inducing remission in mild to moderate CD, while positively affecting the microbiome. Authors explored the tolerability and effectiveness of the T&H diet compared with EEN in children and young adults with mild to moderate uncomplicated CD.

Keywords:

Upadacitinib in psoriatic arthritis with prior TNF-inhibitor failure: a 56-week real-world study

Clin Exp Rheumatol. 2025; Advance online publication Epub ahead of print Doi: 10.55563/clinexprheumatol/gniy9i

Bakay et al. report  that upadacitinib (UPA) demonstrated sustained efficacy across musculoskeletal and skin domains in PsA patients with prior inadequate response to TNF inhibitors, with a safety profile consistent with previous reports.  Authors conducted a retrospective, single-centre observational study evaluating musculoskeletal disease activity, psoriasis, and patient-reported outcomes following initiation of UPA.

Keywords:

November 2025

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

Crohn’s and Colitis 2025 Advance Access: 13 July 2025 Doi: 10.1093/ecco-jcc/jjaf124

Mirikizumab was evaluated for its ability to achieve disease clearance (DC) across two years in adults with moderately to severely active ulcerative colitis within the LUCENT trial programme. DC required concurrent symptomatic, endoscopic, and histologic remission.

Keywords:

Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis

RMD Open 2025;11:e005969 Doi: 10.1136/rmdopen-2025-005969

Ramiro et al. show that bimekizumab (BKZ) reduces enthesitis and peripheral arthritis in patients with nr-axSpA and r-axSpA up to 2 years. Authors assessed the effect of BKZ treatment on the main peripheral manifestations of axSpA, including enthesitis and peripheral arthritis, using a range of measures including DAPSA, to Week 104 in the BE MOBILE 1 and 2 studies.

Keywords:

A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK

Rheumatology 2025 Doi: 10.1093/rheumatology/keaf570 Epub ahead of print

Gollins et al. reported that within this cohort, the Psoriatic arthritis response criteria (PsARC) response to 4th+ lines of b/tsDMARD was not significantly reduced compared with 2nd/3rd line in participants who had failed at least 3 b/tsDMARDs. Authors evaluated the primary clinical response to sequential lines of b/tsDMARD therapy in PsA, focusing on the effectiveness of later line treatments.

Keywords:

Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: A target trial emulation study

Front. Immunol 2025;16:1673970 Doi: 10.3389/fimmu.2025.1673970

Bai et al. reported that JAKi therapy was associated with a reduced risk of incident uveitis compared with TNF inhibitors among patients with AS, PsO, or PsA. Authors conducted a large-scale, real world comparative study which evaluated the risk of incident uveitis among patients with psoriatic disease and AS treated with either TNFi or JAKi.

Keywords:

Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study

Rheumatology 2025 Epub ahead of print doi: 10.1016/S2665-9913(25)00184-5

Bennett et al, showed that tofacitinib treatment in adults with rheumatoid arthritis led to a significant increase in lower limb and thigh muscle volume, accompanied by rises in serum creatinine without evidence of renal impairment.

Keywords:

Clinical efficacy of JAK inhibitors for rheumatoid arthritis patients with poor-prognosis factors: The ANSWER cohort study

Rheumatology 2025 Doi: 10.1093/rheumatology/keaf552 Epub ahead of print

Nozaki et al. showed that JAK inhibitor treatment provided sustained disease control (especially in high-risk RA patients) and promoted GC reduction, although TNF inhibitors remain a standard option. Nozaki et al. evaluated the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor-prognosis factors (PPFs).

Keywords:

October 2025

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): Two phase 3, randomised, placebo-controlled and active-comparator controlled trials

Lancet 2025;406:1363–74 Doi: 10.1016/S0140-6736(25)01576-4

Gold et al. showed that icotrokinra showed superior clinical response rates versus PBO and deucravacitinib in Phase 3 moderate-to-severe plaque PsO trials. Authors evaluated the efficacy and safety of icotrokinra, a targeted oral peptide that selectively binds the IL-23 receptor, compared with both PBO and deucravacitinib in adults with moderate-to-severe plaque PsO.

Keywords:

Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): A multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, Phase 2b trial

Lancet Gastroenterol Hepatol 2025;10:882–95 Doi: 10.1016/S2468-1253(25)00129-3

Danese et al. report that in the TUSCANY-2 study, afimkibart showed a favourable
benefit–risk profile with clinically meaningful improvements and early onset of response during induction, sustained through maintenance, and an acceptable safety profile with no safety signals. Danese et al. describe results from the Phase 2b TUSCANY-2 trial that evaluated the safety and efficacy of 50mg, 150mg, and 450mg doses of afimkibart in adults with moderately-to-severely active UC.

Keywords: